Hematopoietic origin of human natural killer (NK) cells: generation from immature progenitors
- PMID: 7507682
- DOI: 10.1159/000163803
Hematopoietic origin of human natural killer (NK) cells: generation from immature progenitors
Abstract
Human natural killer (NK) cells originate from bone marrow, but little is known about NK cell progenitors and ontogeny. We studied the phenotype and functional activity of NK cells derived from highly purified human bone marrow CD34+ cells, which exhibited neither lytic activity nor expression of surface antigens characteristic of NK (CD56) or T (CD3) cells. However, when cultured with hematopoietic growth factors or feeder layers for up to 4 weeks, up to 86% functional CD56+ cells were seen in the absence of mature T cell development. CD56+ cells appeared in all cultures at 2 or 3 weeks, with the largest percentage in those exposed to IL-2. These studies demonstrated that NK cells arise 'in vitro' from immature bone marrow progenitors and also suggest a separate origin and differentiation pathway for NK and T cells.
Similar articles
-
The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.Blood. 1992 Nov 1;80(9):2182-7. Blood. 1992. PMID: 1384796
-
Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.J Immunol. 1993 Jun 15;150(12):5263-9. J Immunol. 1993. PMID: 7685792
-
Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells.Blood. 1996 Apr 1;87(7):2632-40. Blood. 1996. PMID: 8639878
-
Human natural killer cell development from bone marrow progenitors: analysis of phenotype, cytotoxicity and growth.Nat Immun. 1993 Jul-Oct;12(4-5):209-17. Nat Immun. 1993. PMID: 8257827 Review.
-
Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in?Res Immunol. 1997 Mar-Apr;148(3):195-201. doi: 10.1016/s0923-2494(97)84225-3. Res Immunol. 1997. PMID: 9255874 Review. No abstract available.
Cited by
-
Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies.Front Immunol. 2014 Mar 17;5:95. doi: 10.3389/fimmu.2014.00095. eCollection 2014. Front Immunol. 2014. PMID: 24672522 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials